drugset / Trial / NCT07119931
A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)
NaSingle-groupOpen-labelTreatment
Summary
Major Objectives To evaluate the efficacy of HAIC combined with Iparomlimab and Tuvonralimab injection (QL1706, an Anti-PD-1/CTLA-4 Combined Antibody) plus bevacizumab as a conversion therapy in patients with potentially resectable HCC, assessed by the conversion resection rate.
Timeline
- Start
- 2025-09-10
- Primary completion
- 2027-12-30
- Completion
- 2029-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | — |
| Subject | Levoleucovorin | Unknown | 200 mg/m2 | Other |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Other |
| Subject | QL1706 | Monoclonal antibody | 7.5 mg/kg | — |
| Subject | fluorouracil | Small molecule | 400 mg/m2 | Other |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | Other |